Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Eye Co. Pty Ltd. manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions, which are distributed across 2 distinct art units. This distribution indicates that the company's active patent applications cover diverse technical sub-sectors within the broader biotechnology field. The presence of multiple active matters suggests an ongoing investment in protecting its biological or pharmaceutical innovations.
The prosecution involves 2 distinct examiners, providing a variety of perspectives on the pending claims. AZPURU, CARLOS A is the busiest examiner for the portfolio, currently responsible for 1 pending office action. This means the workload is evenly split, as the total of 2 pending office actions is shared among the 2 distinct examiners. Practitioners should note that each examiner is operating within a different art unit, requiring tailored arguments for each specific technical area. The use of 2 distinct examiners and 2 distinct art units suggests that the company's patent strategy is not centralized under a single point of review.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18139024 | UNIT DOSE PHARMACEUTICAL OF A DRY POWDER OF ONE OR MORE GLUCOCORTICOID OR MINERALOCORTICOID FLUDROCORTISONE ACETATE AND/OR TRIAMCINOLONE ACETONIDE COMPRISED IN A SYRINGE | AZPURU, CARLOS A | 71d |
| 18837905 | TREATMENT OF ANTI-VEGF REFRACTORY OPHTHALMIC RETINAL EYE CONDITIONS | BERRY, LAYLA D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16763409 | COMPOSITION AND METHOD OF TREATMENT FOR DRY A.M.D. (AGE RELATED MACULAR DEGENERATION) | HELLMAN, KRISTINA M | 24d overdue |
| 18139024 | UNIT DOSE PHARMACEUTICAL OF A DRY POWDER OF ONE OR MORE GLUCOCORTICOID OR MINERALOCORTICOID FLUDROCORTISONE ACETATE AND/OR TRIAMCINOLONE ACETONIDE COMPRISED IN A SYRINGE | AZPURU, CARLOS A | 71d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837905 | TREATMENT OF ANTI-VEGF REFRACTORY OPHTHALMIC RETINAL EYE CONDITIONS | BERRY, LAYLA D | — | §102§103§112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18139024 | UNIT DOSE PHARMACEUTICAL OF A DRY POWDER OF ONE OR MORE GLUCOCORTICOID OR MINERALOCORTICOID FLUDROCORTISONE ACETATE AND/OR TRIAMCINOLONE ACETONIDE COMPRISED IN A SYRINGE | AZPURU, CARLOS A | 1617 | §103§112 | Non-Final OA | 71d | Pending | Apr 25, 2023 |
| 16763409 | COMPOSITION AND METHOD OF TREATMENT FOR DRY A.M.D. (AGE RELATED MACULAR DEGENERATION) | HELLMAN, KRISTINA M | 1654 | §112DP | Final Rejection | 24d overdue | Pending | May 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial